Patents by Inventor Kate Dora Games
Kate Dora Games has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210032318Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful prophylactic and therapeutic treatment of Parkinson's disease.Type: ApplicationFiled: April 7, 2020Publication date: February 4, 2021Applicants: Prothena Biosciences Limited, The Regents of the University of CaliforniaInventors: Dale B. Schenk, Eliezer Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward M. Rockenstein, Kate Dora Games
-
Patent number: 10875910Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).Type: GrantFiled: April 23, 2020Date of Patent: December 29, 2020Assignee: PROTHENA BIOSCIENCES LIMITEDInventors: Robin Barbour, Kate Dora Games Thiel, Tarlochan S. Nijjar
-
Publication number: 20200317763Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer' s disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).Type: ApplicationFiled: April 23, 2020Publication date: October 8, 2020Applicant: PROTHENA BIOSCIENCES LIMITEDInventors: Robin Barbour, Kate Dora Games Thiel, Tarlochan S. Nijjar
-
Publication number: 20200299397Abstract: The invention provides blood-brain barrier shuttles comprising monoclonal antibody 5C1 and related antibodies linked to a monovalent binding entity for a blood-brain barrier receptor. The 5C1 antibody binds to an epitope within residues 118-126 of alpha-synuclein. The antibodies are useful, for example, for treating and/or diagnosing synucleinopathies including Lewy body diseases, such as Parkinson's disease, diffuse Lewy body disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Alzheimer's and Parkinson's disease comorbidity, and pure autonomic failure, as well as multiple system atrophy (MSA).Type: ApplicationFiled: February 6, 2020Publication date: September 24, 2020Inventors: Robin Barbour, Kate Dora Games-Thiel, Tarlochan S. Nijjar, Wagner Zago, Olaf Mundigl, Jens Niewoehner, Georg Tiefenthaler
-
Patent number: 10669331Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).Type: GrantFiled: April 16, 2019Date of Patent: June 2, 2020Assignee: PROTHENA BIOSCIENCES LIMITEDInventors: Robin Barbour, Kate Dora Games Thiel, Tarlochan S. Nijjar
-
Patent number: 10562973Abstract: The invention provides blood-brain barrier shuttles comprising monoclonal antibody 5C1 and related antibodies linked to a monovalent binding entity for a blood-brain barrier receptor. The 5C1 antibody binds to an epitope within residues 118-126 of alpha-synuclein. The antibodies are useful, for example, for treating and/or diagnosing synucleinopathies including Lewy body diseases, such as Parkinson's disease, diffuse Lewy body disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Alzheimer's and Parkinson's disease comorbidity, and pure autonomic failure, as well as multiple system atrophy (MSA).Type: GrantFiled: April 8, 2015Date of Patent: February 18, 2020Assignees: Prothena Bioscience Limited, Hoffmann-LaRoche Inc.Inventors: Robin Barbour, Kate Dora Games-Thiel, Tarlochan S. Niijar, Wagner Zago, Olaf Mundigl, Jens Niewoehner, Georg Tiefenthaler
-
Publication number: 20190315843Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).Type: ApplicationFiled: April 16, 2019Publication date: October 17, 2019Applicant: PROTHENA BIOSCIENCES LIMITEDInventors: Robin Barbour, Kate Dora Games Thiel, Tarlochan S. Nijjar
-
Publication number: 20190300598Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful prophylactic and therapeutic treatment of Parkinson's disease.Type: ApplicationFiled: February 21, 2019Publication date: October 3, 2019Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: DALE B. SCHENK, ELIEZER MASLIAH, MANUEL J. BUTTINI, TAMIE J. CHILCOTE, EDWARD M. ROCKENSTEIN, KATE DORA GAMES
-
Patent number: 10301382Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).Type: GrantFiled: August 21, 2018Date of Patent: May 28, 2019Assignee: PROTHENA BIOSCIENCES LIMITEDInventors: Robin Barbour, Kate Dora Games Thiel, Tarlochan S. Nijjar
-
Publication number: 20190062415Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).Type: ApplicationFiled: August 21, 2018Publication date: February 28, 2019Inventors: ROBIN BARBOUR, KATE DORA GAMES THIEL, TARLOCHAN S. NIJJAR
-
Patent number: 10081674Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).Type: GrantFiled: February 10, 2017Date of Patent: September 25, 2018Assignee: PROTHENA BIOSCIENCES LIMITEDInventors: Robin Barbour, Kate Dora Games Thiel, Tarlochan S. Nijjar
-
Publication number: 20170349651Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful prophylactic and therapeutic treatment of Parkinson's disease.Type: ApplicationFiled: May 30, 2017Publication date: December 7, 2017Inventors: Dale B. Schenk, Eliezer Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward M. Rockenstein, Kate Dora Games
-
Publication number: 20170174777Abstract: The invention provides blood-brain barrier shuttles comprising monoclonal antibody 5C1 and related antibodies linked to a monovalent binding entity for a blood-brain barrier receptor. The 5C1 antibody binds to an epitope within residues 118-126 of alpha-synuclein. The antibodies are useful, for example, for treating and/or diagnosing synucleinopathies including Lewy body diseases, such as Parkinson's disease, diffuse Lewy body disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Alzheimer's and Parkinson's disease comorbidity, and pure autonomic failure, as well as multiple system atrophy (MSA).Type: ApplicationFiled: April 8, 2015Publication date: June 22, 2017Inventors: Robin Barbour, Kate Dora Games-Thiel, Tarlochan S. Nijar, Wagner Zago, Olaf Mundigl, Jens Niewoehner, Georg Tiefenthaler
-
Publication number: 20170152310Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).Type: ApplicationFiled: February 10, 2017Publication date: June 1, 2017Inventors: ROBIN BARBOUR, KATE DORA GAMES THIEL, TARLOCHAN S. NIJJAR
-
Patent number: 9605056Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).Type: GrantFiled: October 8, 2013Date of Patent: March 28, 2017Assignee: PROTHENA BIOSCIENCES LIMITEDInventors: Robin Barbour, Kate Dora Games Thiel, Tarlochan S. Nijjar
-
Publication number: 20160184416Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.Type: ApplicationFiled: August 27, 2015Publication date: June 30, 2016Inventors: Dale B. Schenk, Eliezer Masliah, Manuel J. Buttini, Chilcote J. Tamie, Edward Rockenstein, Kate Dora Games
-
Publication number: 20160060331Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful prophylactic and therapeutic treatment of Parkinson's disease.Type: ApplicationFiled: August 31, 2015Publication date: March 3, 2016Inventors: Dale B. Schenk, Eliezer Masliah, Manuel J. Buttini, Chilcote J. Tamie, Edward M. Rockenstein, Kate Dora Games
-
Publication number: 20150259404Abstract: The invention provides monoclonal antibody 5Cl and related antibodies. The 5Cl antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).Type: ApplicationFiled: October 8, 2013Publication date: September 17, 2015Applicant: PROTHENA BIOSCIENCES LIMITEDInventors: Robin Barbour, Kate Dora Games Thiel, Tarlochan S. Nijjar
-
Patent number: 9034337Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.Type: GrantFiled: February 23, 2007Date of Patent: May 19, 2015Assignee: Prothena Biosciences LimitedInventors: Dale B. Schenk, Eliezar Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Kate Dora Games
-
Publication number: 20140127131Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).Type: ApplicationFiled: October 8, 2013Publication date: May 8, 2014Inventors: ROBIN BARBOUR, KATE DORA GAMES THIEL, TARLOCHAN S. NIJJAR